Immunogenicity and safety study of GlaxoSmithKline Biologicals’ Infanrix hexa™ vaccine in healthy infants in India

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-003427-10

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To assess the immunological response to the study vaccine in terms of seroprotection status for diphtheria, tetanus, polio, hepatitis B (HB) and Haemophilus influenza type b (Hib) anti-gens, and in terms of vaccine response for the pertussis (PT) antigens, one month after the third dose of the primary vacci-nation.


Critère d'inclusion

  • Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, polio and Hib diseases